Paul Mampilly has spent over 25 years researching stocks and investment trends. Thanks to his diligent hard work, he has helped his wealthy clients and hedge fund customers build even larger fortunes. A few years ago, he grew tired of the Wall Street rat race. He wanted to spend more time with his family. And he grew tired of helping the already-rich grow even larger fortunes. He wanted to help average, hardworking professionals and small businesspeople build their wealth so they would have a comfortable retirement.
— Paul Mampilly (@Paul_M_Guru) October 26, 2017
He started out in 1991 as an analyst for such major banks as Deutsche Bank, the Royal Bank of Scotlant, ING and Bankers Trust. He’s worked for the aristocracy of Europe and for private Swiss banks. He’s covered healthcare and biotechnology stocks as a portfolio manager. He has helped to manage a $23 billion mutual fund. In 2008, Barron’s named his $6 billion hedge fund one of the best in the world. He entered a prestigious investing contest put on by the Templeton Foundation. Despite the Great Recession when all asset classes around the world collapsed in price, he turned $50 million into $88 million, and did it without shorting.
In 2014, Mampilly wrote an interesting article predicting a long-term boom in biotech stocks even though, at the time, many “experts” said the biotechnology sector was in a “bubble.” Certainly, stock prices were up, but so was the quality of the products many of these companies produced.
Mampilly pointed out that biotech products affect everybody. We’re all vulnerable to various diseases and medical problems. If we have an illness, we want the cure, especially when it’s a life-threatening illness.
And biotech is new, going back only to 1980. Before healthcare simply didn’t know enough. Now, new research continues to discover new things about our biologies and how to use that information to treat diseases. As he points out, just 20 years ago, chronic myeloid leukemia was a death sentence. An effective treatment did not exist. Then some dedicated scientists discovered a compound that inhibits the tyrosine protein inhibitor of CML. They had to push a major pharmaceutical firm to fund clinical trials. But when they carried out those trials, the results were so spectacular that the FDA approved Gleevec in record time. Today, many thousands of people manage their CML simply by taking one pill a day, with almost no side effects.
And many companies are now looking for other kinase inhibitors and other types of drugs to cure various forms of cancer.
About Paul Mampilly: seekingalpha.com/user/48491120/stocktalks